Literature DB >> 7442721

Metabolic studies on the new fasciolicidal drug, closantel.

H J Kane, C A Behm, C Bryant.   

Abstract

Studies of the metabolic disturbances caused in Fasciola hepatica by closantel have been carried out in vitro and in fluke recovered from treated sheep. Fluke exposed to the anthelmintic under both conditions exhibit increased carbohydrate mobilisation, increased end-product formation, especially of succinate, diminished ATP synthesis, increased oxaloacetate/malate ratios, and increased internal concentrations of pyruvate. No specific enzyme inhibition was detected. These results are consistent with the view that closantel acts as an uncoupler of oxidative phosphorylation by increasing mitochondrial permeability.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7442721     DOI: 10.1016/0166-6851(80)90052-3

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  5 in total

Review 1.  1,1-Diaryl compounds as important bioactive module in pesticides.

Authors:  Xuelian Liu; Yumei Xiao; Jia-Qi Li; Bin Fu; Zhaohai Qin
Journal:  Mol Divers       Date:  2018-12-05       Impact factor: 2.943

2.  The effect of the hydrogen ionophore closantel upon the pharmacology and ultrastructure of the adult liver fluke Fasciola hepatica.

Authors:  P J Skuce; I Fairweather
Journal:  Parasitol Res       Date:  1990       Impact factor: 2.289

3.  Ultrastructural observations on oral ingestion and trans-tegumental uptake of clorsulon by the liver fluke, Fasciola hepatica.

Authors:  M Meaney; S Haughey; G P Brennan; I Fairweather
Journal:  Parasitol Res       Date:  2005-01-06       Impact factor: 2.289

4.  Transmission electron microscope study of the ultrastructural changes induced in the tegument and gut of Fasciola hepatica following in vivo drug treatment with clorsulon.

Authors:  M Meaney; I Fairweather; G P Brennan; A B Forbes
Journal:  Parasitol Res       Date:  2004-01-09       Impact factor: 2.289

Review 5.  Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC.

Authors:  Michael J Grant; Roy S Herbst; Sarah B Goldberg
Journal:  Nat Rev Clin Oncol       Date:  2021-06-24       Impact factor: 66.675

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.